Mechanism of liposome arsenic trioxide regulating tumor microenvironment and sensitizing tumor immune response after radiofrequency ablation - Takeaways - MDSpire

Mechanism of liposome arsenic trioxide regulating tumor microenvironment and sensitizing tumor immune response after radiofrequency ablation

  • By

  • Chao Liang

  • Shuguang Ju

  • Hao Li

  • Daqian Han

  • Jiacheng Wang

  • Yangyang Niu

  • Jianzhuang Ren

  • Xinwei Han

  • Xuhua Duan

  • June 29, 2026

  • 0 min

Share

  • 1

    Preoperative administration of liposome arsenic trioxide (LATO) aims to downregulate HIF-1α in residual tumors after incomplete radiofrequency ablation (iRFA).

  • 2

    LATO significantly decreases the expression of PCNA, CD31, and HIF-1α in residual tumors, promoting immune cell infiltration and prolonging survival in mice.

  • 3

    The combination of LATO and anti-PD-L1 antibody therapy further reduces tumor proliferation and enhances the antitumor immune response post-ablation.

  • 4

    Incomplete tumor necrosis after RFA is primarily due to factors like increased blood flow and energy deposition limitations within the tumor.

  • 5

    Liposomal drug delivery systems like LATO improve the therapeutic index of arsenic trioxide by enhancing tumor site deposition and reducing systemic toxicity.

Original Source(s)

Related Content